Cardiology
Every heartbeat tells a story, and cardiologists listen carefully to diagnose, treat, and protect the rhythm of life.
Fatima, 52, had metastatic ovarian cancer. She responded poorly to the first-line regimen, then progressed on the second. Her husband begged me to try something else. I reluctantly enrolled her in a Phase II clinical trial for an experimental PARP inhibitor.
To my surprise, her CA-125 plummeted. Months passed, then a year. Her disease stabilized longer than we hoped. She now volunteers in our infusion center, supporting women walking her old path.
She now volunteers in our infusion center, supporting women walking her old path.
The Lesson Learned
Even when the odds are slim, hope and science deserve a chance to meet. Trial enrollment isn’t a last resort—it’s a frontier.
